Nutrition & Santé
This article was originally published in The Tan Sheet
Executive Summary
Novartis has agreed to divest its Nutrition & Santé business to ABN AMRO Capital France for $260 mil. (€1=$1.17) on a cash and debt-free basis, the firm announces Nov. 29. Divestiture is expected to take place in first quarter 2006. Nutrition & Santé comprises the remainder of Novartis' Health & Functional Food business unit; the firm sold a number of assets to Associated British Foods in November 2002 (1"The Tan Sheet" Oct. 14, 2002, In Brief). Nutrition & Santé produces functional foods Gerblé and Céréal, weight loss products Gerlinéa, Pesoforma and Milical and sports nutrition product line Isostar. The firm markets primarily in France, Spain, Portugal, Italy and the Benelux region...
You may also be interested in...
Ovaltine sale overseas
UK-based Associated British Foods picks up rights to malt-based product line worldwide, except for U.S. and Puerto Rico, with acquisition of Novartis' Food & Beverage business for about $267.5 mil. ($1=€1.02), firms announce Oct. 8. Himmel Nutrition has held U.S. licensing rights to Ovaltine since 1992, according to Novartis. Divested F&B business generated approximately $239.5 mil. in 2001 sales, constituting 43% of Health & Functional Food division's revenue; Novartis announced plans to divest the division in February (1"The Tan Sheet" Feb. 11, 2002, p. 12). Negotiations to sell other H&FF businesses, including Sports Nutrition division, "are proceeding," firm says. Benefiber, Resource Wellness supplement lines are housed in Novartis' Medical Nutrition unit, which is not for sale...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.